Vericel to Present at Multiple Upcoming Investor Conferences

Rhea-AI Summary

Vericel (NASDAQ:VCEL), a specialized company in advanced therapies for sports medicine and severe burn care markets, has announced its participation in three major upcoming investor conferences in March 2025:

• TD Cowen 45th Annual Health Care Conference - March 5, 2025
• Canaccord Genuity 2025 Musculoskeletal Conference - March 10, 2025
• Leerink Partners 2025 Global Healthcare Conference - March 12, 2025

The company will make presentations at each event, with webcasts available through Vericel's Investor Relations website section at investors.vcel.com.

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences:

• TD Cowen 45^th Annual Health Care Conference on Wednesday, March 5, 2025
• Canaccord Genuity 2025 Musculoskeletal Conference on Monday, March 10, 2025
• Leerink Partners 2025 Global Healthcare Conference on Wednesday, March 12, 2025
  

A webcast of the presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

FAQ

Which investor conferences will Vericel (VCEL) attend in March 2025?

Vericel will present at three conferences: TD Cowen Health Care Conference (March 5), Canaccord Genuity Musculoskeletal Conference (March 10), and Leerink Partners Global Healthcare Conference (March 12).

How can investors access Vericel's (VCEL) conference presentations?

Investors can access webcasts of the presentations through Vericel's Investor Relations website at investors.vcel.com.

What markets does Vericel (VCEL) specialize in?

Vericel specializes in advanced therapies for the sports medicine and severe burn care markets.

When is Vericel's (VCEL) presentation at the TD Cowen Healthcare Conference?

Vericel will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025.